NCT03472846

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: Female
• Age: 60 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Detailed description

Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral density will be investigated. These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the diagnosis of osteoporosis and targeted therapeutic treatment of patients.

Conditions

• Postmenopausal Osteoporosis
• Diabetes Type 2

Interventions

Type	Name	Description
DRUG	Prolia, 60 Mg/mL Subcutaneous Solution	antiresorptive treatment with Prolia
DRUG	Teriparatide	osteoanabolic treatment with Forsteo

Timeline

• Start date: 2017-03-01
• Primary completion: 2022-09-01
• Completion: 2022-09-30
• First posted: 2018-03-21
• Last updated: 2023-01-26

Locations

1 site across 1 country: Austria